Ayisha Sharma
Reporter
Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from University College London and an NCTJ diploma in multimedia journalism. Ayisha is interested in psychiatric disorders and drug development focused on the microbiome.
Latest From Ayisha Sharma
Sanofi Reports Uninspiring Q4 Sales Amid Skepticism On Dupixent’s COPD Potential
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
Executives On The Move: Grey Wolf Therapeutics, Fresh Tracks Therapeutics And More
Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.
Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval
The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.
Novo’s Wegovy Back On Track In Q4 But Broader Supply Issues Remain
Now that US supply of the Danish firm’s blockbuster obesity product is back in full swing, Novo is focusing on diversifying its pipeline to reduce dependence on its GLP-1 franchise.
Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.
Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.